Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00779688 · ClinicalTrials.gov registry record
A Registry of Patients Undergoing Cellvizio Endomicroscopy and Endoscopic Retrograde Cholangiopancreatography(ERCP) Imaging Procedures for Diagnosing Pancreatic and Bile Duct Cancers
A clinical trial of Pancreatic Cancer and Bile Duct Cancer, sponsored by Mauna Kea Technologies.
- Completed
- Registry status
- 130
- Enrollment target
- 6
- Study locations
NCT00779688 is a study of Pancreatic Cancer and Bile Duct Cancer that has completed, run by Mauna Kea Technologies. The registered enrollment target is 130 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (67% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT00779688, a study of Pancreatic Cancer and Bile Duct Cancer, has completed, sponsored by Mauna Kea Technologies.
- COMPLETED
- Registry status
- 130 participants
- Enrollment target
- 6
- Study locations
Study Summary
This registry will collect data from patients routinely undergoing an ERCP and Cellvizio endomicroscopy procedure (and optionally an additional cholangiopancreatoscopy procedure) due to suspected pancreatic or bile duct cancer. The objective is to determine if endomicroscopy images collected using the marketed Cellvizio device may help endoscopists more accurately diagnose, in conjunction with traditional tissue sampling techniques, whether a suspected lesion is malignant or benign.
Conditions Studied
Interventions
- DEVICE Probe-based confocal laser endomicroscopy
Study Locations (6)
Colorado
- University of Colorado Hospital - Aurora
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
New York
- New York Presbyterian Hospital/Columbia University Medical Center - New York
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Other
- Institut Paoli-Calmettes - Marseille
Bavaria
- Klinikum rechts der Isar - Munich
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00779688
The ClinicalTrials.gov registry entry for NCT00779688 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (67% lower). The listed sponsor is Mauna Kea Technologies, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Probe-based confocal laser endomicroscopy is the first listed.
NCT00779688 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Colorado, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT00779688 about?
NCT00779688 is a clinical study titled "A Registry of Patients Undergoing Cellvizio Endomicroscopy and Endoscopic Retrograde Cholangiopancreatography(ERCP) Imaging Procedures for Diagnosing Pancreatic and Bile Duct Cancers". This registry will collect data from patients routinely undergoing an ERCP and Cellvizio endomicroscopy procedure (and optionally an additional cholangiopancreatoscopy procedure) due to suspected pancreatic or bile duct cancer. The objective is to determine if endomicroscopy images collected using t...
What is the current status of trial NCT00779688?
This trial is currently completed. The enrollment target is 130 participants. The study started on 2008-11. Estimated completion is 2010-10.
What conditions does trial NCT00779688 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Bile Duct Cancer.
What interventions are being tested in trial NCT00779688?
The interventions under investigation include: Probe-based confocal laser endomicroscopy (DEVICE).
Who is sponsoring clinical trial NCT00779688?
This trial is sponsored by Mauna Kea Technologies, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00779688 being conducted?
This trial has 6 study locations across Colorado, Massachusetts, New York, Pennsylvania, Bavaria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.